Stock Price Prediction

NRSN stock is currently trading at $1.13, reflecting a 17% decline. The bullish view hinges on the company’s recent advancements in ALS treatment with PrimeC, which has shown promising Phase IIb results and is set to enter Phase III trials by mid-2025. Additionally, its partnership with a global pharmaceutical company for commercialization could drive significant upside if milestones are achieved.

NRSN stock is currently trading at $1.13, down nearly 17% as of the latest data. The bearish view stems from the company's inability to benefit directly from recent share offerings, which only add expenses without improving its financial position. Additionally, while its ALS drug PrimeC shows promise, the stock faces dilution risks and slow revenue growth, making it unattractive in the short term.